(Total Views: 724)
Posted On: 03/27/2021 9:25:53 AM
Post# of 148893
Good morning to all,
LONG COVID is a large market opportunity. However, it is a very complex condition (as everybody knows).
Perhaps one of the persons that know this best is Dr. Patterson. He has a sophisticated lab (Allowing him to make real-time measurements), he was well positioned from the beginning of the Pandemic to start working on COVID and he has the knowledge to pursue a possible solution in the right direction.
In our clinical trial we should be simultaneously paying attention to the latest research in this area so we can tailor the PE's and trial design to optimize our results and potential inclusion in the arsenal.
In the last video around 20:10 there is the following question & answer interaction (the highlight are mine):
QUESTION: Does the treatment even work ?? Do we have anyone that has completely recovered ???
Dr. Patterson ANSWER: The most important aspect of treating Long Covid is combinations; the single drugs don’t seem to work as well as using a variety of combinations, and now that we found what we think is the underlying cause of Long Covid, we are even more confident that the panels we have chosen are addressing the pathogenesis of Long Covid. So, we are very exited of that, and what we are targeting, because it turns out that what we are targeting is what it is the hart of all the symptoms of Long COVID and, again, that will be explained in more detail in the paper we are vigorously putting together right now.
So, we are trying to probe LL works and surely we will conclude it does. However, at the end, LL will probably be part of the solution and not the solution itself.
As I said before, we should be exploring strategic alliances to get LL included as apart of Long Covid treatment rather than launching a trial were we will probe that we indeed do some good but were meeting significant EP might probe to be very difficult due to the fact that Long Covid needs to be attacked from several fronts.
If not, ask those that are trying to treat it.
Honestly, I would be wiling to pay NP's plane ticket from Vancouver to San Carlos to go and kiss BP's bottom side, tell him that there was a miss understanding and "bring him in". It is maybe too late for this, and I am sure some will not agree, but, believe me, this is strictly business.
Please remember, we don't have a R&D team/lab and it seems that doing "exploratory trials" is not an efficient way of making discovery into the benefits of LL in Long Covid.
Once again, this is a very complex condition. We might have one piece of the puzzle but not the whole enchilada and running trials to find out seems to me like a time and money expensive proposition.
LONG COVID is a large market opportunity. However, it is a very complex condition (as everybody knows).
Perhaps one of the persons that know this best is Dr. Patterson. He has a sophisticated lab (Allowing him to make real-time measurements), he was well positioned from the beginning of the Pandemic to start working on COVID and he has the knowledge to pursue a possible solution in the right direction.
In our clinical trial we should be simultaneously paying attention to the latest research in this area so we can tailor the PE's and trial design to optimize our results and potential inclusion in the arsenal.
In the last video around 20:10 there is the following question & answer interaction (the highlight are mine):
QUESTION: Does the treatment even work ?? Do we have anyone that has completely recovered ???
Dr. Patterson ANSWER: The most important aspect of treating Long Covid is combinations; the single drugs don’t seem to work as well as using a variety of combinations, and now that we found what we think is the underlying cause of Long Covid, we are even more confident that the panels we have chosen are addressing the pathogenesis of Long Covid. So, we are very exited of that, and what we are targeting, because it turns out that what we are targeting is what it is the hart of all the symptoms of Long COVID and, again, that will be explained in more detail in the paper we are vigorously putting together right now.
So, we are trying to probe LL works and surely we will conclude it does. However, at the end, LL will probably be part of the solution and not the solution itself.
As I said before, we should be exploring strategic alliances to get LL included as apart of Long Covid treatment rather than launching a trial were we will probe that we indeed do some good but were meeting significant EP might probe to be very difficult due to the fact that Long Covid needs to be attacked from several fronts.
If not, ask those that are trying to treat it.
Honestly, I would be wiling to pay NP's plane ticket from Vancouver to San Carlos to go and kiss BP's bottom side, tell him that there was a miss understanding and "bring him in". It is maybe too late for this, and I am sure some will not agree, but, believe me, this is strictly business.
Please remember, we don't have a R&D team/lab and it seems that doing "exploratory trials" is not an efficient way of making discovery into the benefits of LL in Long Covid.
Once again, this is a very complex condition. We might have one piece of the puzzle but not the whole enchilada and running trials to find out seems to me like a time and money expensive proposition.
(17)
(0)
Scroll down for more posts ▼